NanoString Technologies, Inc. Stock Price, News & Analysis

NanoString Technologies (NASDAQ:NSTG) announced the commercial launch of the Whole Transcriptome Atlas (WTA) for human and mouse tissue research, enhancing the GeoMx Digital Spatial Profiler (DSP) portfolio. The WTA provides a comprehensive view of all protein-coding genes and expands applications into neuroscience and developmental biology, complementing existing offerings in oncology and immunology. This launch signifies a key milestone for the company, with strong interest noted in its Technology Access Program. The WTA's capabilities will be showcased at the upcoming Spatial Genomics Summit on February 23.

NanoString Technologies, a leader in life science tools, will present at the 10th Annual SVB Leerink Global Healthcare Conference. CEO Brad Gray is set to speak on February 25th, 2021, at 10:00am ET. Interested listeners can access the live webcast and slides via the company's website, with a replay available one hour post-event for 60 days. The nCounter® Analysis System by NanoString is widely used in research, cited in over 4,000 publications, and supports biomarker discovery. For details, visit www.nanostring.com.

NanoString Technologies, Inc. (NASDAQ:NSTG) will disclose its fourth quarter and fiscal year 2020 results on March 1, 2021, after market close. A conference call hosted by company management will follow at 4:30 PM ET to discuss the results and provide a business update. Interested parties are encouraged to register in advance for the call. A replay will be accessible from March 1, 2021, at 7:30 PM ET until March 8, 2021. NanoString is recognized for its innovative life science tools, including the nCounter® Analysis System and GeoMx™ Digital Spatial Profiler.

NanoString Technologies (NASDAQ:NSTG) has announced a significant advancement in cancer research with the publication of a study in Nature Medicine utilizing its GeoMx® Digital Spatial Profiler (DSP) and Whole Transcriptome Atlas (WTA). Conducted by the Broad Institute, the study focuses on profiling sarcoma tissue and reveals novel insights into the immune response against synovial sarcoma. This peer-reviewed paper demonstrates GeoMx's capacity for high-plex spatial analysis, highlighting opportunities for future immunotherapy development.

NanoString Technologies, Inc. (NASDAQ:NSTG) reported strong preliminary financial results for Q4 and the fiscal year ending December 31, 2020, surpassing revenue expectations in all categories. The company generated $35.7 million in Q4 product and service revenue, driven by strong demand for its nCounter and GeoMx products. The total addressable market for spatial biology was updated to $12 billion, highlighting growth opportunities. Cash and short-term investments stood at approximately $440 million, indicating a solid financial position.

NanoString Technologies (NASDAQ:NSTG) has been recognized by Nature Methods as the Method of the Year for 2020 for its advancements in spatially-resolved transcriptomics. This recognition highlights the significance of spatial context in biological research, which has been enhanced by the introduction of the GeoMx® Digital Spatial Profiler (DSP). Launched in 2019, the GeoMx® DSP offers high-plex profiling capabilities, marking a major advancement in understanding cellular interactions. The company believes that innovations in spatial analysis will lead to significant advancements in functional genomics and precision medicine.

NanoString Technologies (NASDAQ:NSTG) announced its participation in the 39th Annual J.P. Morgan Virtual Healthcare Conference. CEO Brad Gray will present on January 13th, 2021, at 2:50 PM ET. The live webcast, including slides, will be accessible via the company’s investor website, with a replay available for 60 days post-event. NanoString is recognized for its nCounter® Analysis System, which has been cited in over 4,000 peer-reviewed publications, and its GeoMx® Digital Spatial Profiler, both pivotal in life sciences research.

NanoString Technologies (NASDAQ:NSTG) announced a peer-reviewed study published in Nature Communications that utilized its GeoMx® Digital Spatial Profiler (DSP) to analyze immune responses in SARS-CoV-2 infection. This study revealed crucial insights into the spatial heterogeneity of immune responses, highlighting the correlation between viral location and immune activity. The GeoMx DSP platform enabled high-plex spatial profiling of formalin-fixed samples, addressing challenges in COVID-19 research. The findings have potential implications for future therapeutic applications and clinical trials.

NanoString Technologies (NASDAQ:NSTG) has announced the development of a new spatial molecular imaging platform that allows for multiplexed analysis of RNA and protein expression at the single-cell level within tissue samples. This innovative solution leverages the company's advanced Hyb & Seq chemistry, capable of analyzing 1,000+ genes simultaneously. The platform aims to fill the gap for high-plex spatial analysis, enhancing research on cellular interactions in tumors and diseases. A full commercial launch is anticipated in the second half of 2022.